The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...

Gene therapy developer bluebird bio (NASDAQ:BLUE) announced Friday its plans to become a privately held biotech as part of an M&A agreement with private equity firms, Carlyle Group (NASDAQ:CG) and SK ...

Blue Bird Corporation (BLBD) recently announced fiscal Q1 results, beating top and bottom-line expectations. While the ...

A pair of investors will acquire bluebird bio in a deal worth only $29 million upfront after the gene therapy maker ran out ...

Blue Bird Corporation is a compelling investment due to its focus on electric school buses and attractive stock valuation despite recent performance setbacks. Read more here.

KBC Group NV’s holdings in Blue Bird were worth $55,000 as of its most recent SEC filing. A number of other hedge funds have also recently bought and sold shares of BLBD.

Analysts at DA Davidson boosted their FY2025 EPS estimates for Blue Bird in a note issued to investors on Friday, February 7th. DA Davidson analyst M. Shlisky now anticipates that the company will ...

Analysts have been eager to weigh in on the Consumer Cyclical sector with new ratings on Blue Bird (BLBD – Research Report) and Alibaba (BABA ...

Blue Bird (NASDAQ:BLBD) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of ...

MACON, Ga.--(BUSINESS WIRE)--Blue Bird Corporation (Nasdaq: BLBD), the leader in electric and low-emission school buses, has appointed John Wyskiel to the position of President and CEO ...